{"ticker": {"uuid": "8a10c1a5-844b-4d15-9d75-017de2b1da5e", "symbol": "COCP", "name": "Cocrystal Pharma Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "What's Driving the Micro-Cap Mania in SKYQ and COCP", "summary": "This article examines the explosive premarket surges in micro-cap stocks Sky Quarry (SKYQ) and Cocrystal Pharma (COCP), driven by significant catalysts. SKYQ's rally is attributed to strategic Nevada refinery talks and rising Brent crude prices, despite its concerning financial h", "url": "https://www.kavout.com/market-lens/what-s-driving-the-micro-cap-mania-in-skyq-and-cocp", "source_name": "Kavout | AI", "published_at": "2026-07-11T14:11:13", "published_display": "11 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cocrystal Pharma Inc \u2013 FWB:8CC", "summary": "This article provides financial information for Cocrystal Pharma Inc (FWB:8CC) on the Frankfurt Stock Exchange, specifically focusing on its \"Price to book forward\" metric. The content indicates that the market is closed with no trades and gives a general overview of the company'", "url": "https://www.tradingview.com/symbols/FWB-8CC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T01:08:58", "published_display": "11 Jul 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Holds Near Key Support After Slight Decline - PCR Extreme", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQcGk2N2FvS1NPOEpNNU95TE9HVUtJRVB0ZExabnE2Y1dKdXU1cHJEdVdaZFlVSlF1WFpfcldLcG1IblY2NkJod0FTOUg3Y053SjZwZ210TVR2d2ttY05US1otWVFHd1Yxa3Y0Z2JqeWNzM2V6OV9LZVA2N084WWZxNng2RFJFbHQ2MUI0N3JibUJlTEpnYkg4ZGZuNnYxR05vbUlQbGR4Y2hJV0lHb0E?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T16:34:26+00:00", "published_display": "08 Jul 2026 16:34", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP - Cocrystal Pharma Inc Dividends", "summary": "This page provides a detailed financial overview of Cocrystal Pharma Inc (COCP), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists dividend information (all showing as unavailable), performance metrics over different", "url": "https://finviz.com/stock?t=COCP&p=w&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-06T00:40:47", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Inches Up as Stock Tests Key Resistance Levels - Diamond Pattern", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbHNSOHRSbkVIcnVkT0x3VDc3YVZubjVBQVhadjluSDZFdllYem9Zcl9zd0RXZGVLcFpvd0VCcUg5ZU1XTUpUM25RLWxRVGpKNzluZjVkWlJXWFFXWHhWNEx3MVU1cG10VUFMWmhhQlc5eEtVWXNObHZMZjBCLUtQS19JcXMya3BkUXA0R2RXSkNwN01tb3JacUpid1N3TVNucEJDWnNxcEhqaFlUS1I5WVJaUEZuaUZt?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cocrystal Pharma, Inc. \u2013 NASDAQ:COCP", "summary": "This page provides financial information for Cocrystal Pharma, Inc. (NASDAQ: COCP), specifically focusing on its forward price-to-sales ratio. It indicates that the company's market is currently closed with no trades. The content highlights the availability of financial data, new", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:10:43", "published_display": "27 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cocrystal Pharma, Inc. \u2013 NASDAQ:COCP", "summary": "The article focuses on the enterprise value to revenue forward metric for Cocrystal Pharma, Inc. (NASDAQ:COCP). It appears to be a financial data point or analysis, although no specific numerical data is provided in the content. The layout suggests it's a page from a financial tr", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:14", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8CC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cocrystal Pharma Inc (8CC) stock, including analyst price targets, historical performance data, and financial metrics. It highlights that analysts have a max estimated price of 8.61 EUR and a min of 6.89 EUR for 8CC. The piece also covers curr", "url": "https://www.tradingview.com/symbols/GETTEX-8CC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:59", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cocrystal Pharma Inc \u2013 LS:A3DWYX", "summary": "The article provides information regarding the \"Price to book forward\" for Cocrystal Pharma Inc (LS:A3DWYX) on TradingView. It appears to be a financial data point for the company, accessible through the platform's financials section. The content primarily lists navigation and fo", "url": "https://www.tradingview.com/symbols/LS-A3DWYX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:41", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc Actuals & Estimates (NASDAQ:COCP)", "summary": "The article provides actuals and estimates for Cocrystal Pharma, Inc. (COCP) stock, including historical price data, analyst forecasts, financial metrics, and company information. It details COCP's current price, market capitalization, earnings, revenue, and upcoming earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:14", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma(COCP) Stock Options Chain | Quotes & News", "summary": "This article provides access to the stock options chain, quotes, and news for Cocrystal Pharma (COCP). It serves as a resource for investors and analysts interested in detailed financial information and market performance related to the company.", "url": "https://www.moomoo.com/stock/COCP-US/options-chain?chain_id=Name1K9-3FXPhg.1ksbi40&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A39,%22f%22%3A%22www.moomoo.com%2Fus%2Fhant%2Flearn%2Fdetail-what-is-a-roth-ira-71734-220827203%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T09:10:43", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Cocrystal Pharma, Inc. (COCP) stock, including current price, historical performance, and analyst forecasts for 2027. It details analyst price targets, past earnings, revenue, and market capitalization, along with key financial dates like the ", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:41", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cocrystal Pharma Inc (COCP), featuring its current price momentum score, support and resistance levels, and a detailed breakdown of various technical indicators and moving averages. The analysis suggests the stock is suitable for rang", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/technical", "source_name": "TradingKey", "published_at": "2026-06-22T19:09:28", "published_display": "22 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Cocrystal Pharma Inc (COCP), noting its current financial score of 6.43, which ranks it 252 out of 389 in the Biotechnology & Medical Research industry. While its financial status is robust, its operating efficiency is low. The report", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T07:10:33", "published_display": "19 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Cocrystal Pharma Inc (COCP), listing major individual and institutional holders and their respective proportions. It includes information on shareholder types, institutional shareholding trends over several quarters, and recent sh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:56", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on Cocrystal Pharma Inc (COCP) regarding its dividends and stock splits. It notes that the company has distributed no dividends over the past five years and details a series of 12-to-1 reverse merger stock splits that occurred on October 10, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:14", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Cocrystal Pharma Inc (COCP) by business segments and regional contributions. However, it explicitly states that relevant data for these breakdowns have not been disclosed by the company. The page displays cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:14", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cocrystal Pharma Inc (COCP), highlighting its current earnings forecast score of 8.00 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $8.00 with a \"Buy\" rating. The report also includes ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T05:09:46", "published_display": "17 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein as New CEO \u2013 Leadership Transition and Company Details", "summary": "Cocrystal Pharma, Inc. has announced the appointment of James Sapirstein as its new Chief Executive Officer, detailed in a recent 8-K filing. The appointment emphasizes a transparent transition with no related party transactions and includes stock-based incentives for Sapirstein,", "url": "https://www.minichart.com.sg/2026/06/09/cocrystal-pharma-appoints-james-sapirstein-as-new-ceo-leadership-transition-and-company-details/", "source_name": "Minichart", "published_at": "2026-06-09T15:10:19", "published_display": "09 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP)", "summary": "Cocrystal Pharma, Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. He will receive an annual salary of $265,000, a target bonus of 50% of his base salary, and stock options for 235,000 shares, with a potential for an additional 235,00", "url": "https://www.stocktitan.net/sec-filings/COCP/8-k-cocrystal-pharma-inc-reports-material-event-ff2bd36f5245.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:10:19", "published_display": "09 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer", "summary": "Cocrystal Pharma Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Sapirstein brings extensive biopharma leadership and antiviral development experience, having led 23 product launches in his career. He replaces former Co-CEOs Sam Lee ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cocrystal-pharma-appoints-james-sapirstein-110000949.html", "source_name": "Market source", "published_at": "2026-06-05T02:09:32", "published_display": "05 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer", "summary": "Cocrystal Pharma has appointed James Sapirstein as its new Chief Executive Officer. Sapirstein brings extensive experience in the pharmaceutical industry, and his leadership is expected to guide the company's strategic initiatives and growth. This appointment marks a significant ", "url": "https://www.moomoo.com/news/post/71000136/cocrystal-pharma-appoints-james-sapirstein-as-chief-executive-officer?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-04T23:40:01", "published_display": "04 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc. Plans to Appoint James Sapirstein as A Member of the Board of Directors", "summary": "Cocrystal Pharma Inc. announced its plan to appoint James Sapirstein to its Board of Directors. Sapirstein brings extensive pharmaceutical industry leadership, development, and business development experience, having led 23 product launches and held executive roles at Contravir P", "url": "https://www.marketscreener.com/news/cocrystal-pharma-inc-plans-to-appoint-james-sapirstein-as-a-member-of-the-board-of-directors-ce7f5ddcd18af220", "source_name": "www.marketscreener.com", "published_at": "2026-06-03T23:10:24", "published_display": "03 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan", "summary": "Cocrystal Pharma Inc.'s CEO, James Sapirstein, has been granted 235,000 stock options under the company's 2025 Equity Incentive Plan. These options have an exercise price of $1.12 per share and will vest in four equal annual installments starting June 3, 2027, with an expiration ", "url": "https://www.stocktitan.net/sec-filings/COCP/form-4-cocrystal-pharma-inc-insider-trading-activity-c19e0de1498c.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:41:12", "published_display": "03 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3", "summary": "Cocrystal Pharma's CEO, James Sapirstein, has filed an initial Form 3 with the SEC, establishing his status as an insider of the company. This filing is required for officers, directors, and large shareholders when they assume such roles, but it does not indicate any current stoc", "url": "https://www.stocktitan.net/sec-filings/COCP/form-3-cocrystal-pharma-inc-initial-statement-of-beneficial-ownership-daf6995ffce9.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:41:12", "published_display": "03 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP - Cocrystal Pharma Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and company overview for Cocrystal Pharma Inc (COCP), including financial data, performance metrics, and recent news releases. It also lists insider transactions by Director Phillip Frost. The company is a clinical-stage biotechnology ", "url": "https://finviz.com/stock?t=COCP", "source_name": "Finviz", "published_at": "2026-06-03T11:13:18", "published_display": "03 Jun 2026 11:13", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antiviral executive James Sapirstein takes helm at Cocrystal Pharma", "summary": "Cocrystal Pharma (COCP) has appointed James Sapirstein as its new Chief Executive Officer, effective immediately, and plans to add him to the Board of Directors. Sapirstein brings extensive biopharma leadership and antiviral development experience, having participated in or led 2", "url": "https://www.stocktitan.net/news/COCP/cocrystal-pharma-appoints-james-sapirstein-biopharma-industry-leader-leavplspek84.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:41:12", "published_display": "03 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran antiviral leader James Sapirstein to head Cocrystal Pharma (NASDAQ: COCP)", "summary": "Cocrystal Pharma (NASDAQ: COCP) has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Sapirstein, who brings extensive experience in the biopharma industry and antiviral development, will also join the Board of Directors. Former Co-CEOs Sam Lee", "url": "https://www.stocktitan.net/sec-filings/COCP/8-k-cocrystal-pharma-inc-reports-material-event-2e5a52653fc3.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:41:12", "published_display": "03 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein, Biopharma", "summary": "Cocrystal Pharma Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Mr. Sapirstein brings extensive biopharma industry leadership and antiviral development experience and will also join the company's Board of Directors. The previous Co-", "url": "https://www.globenewswire.com/news-release/2026/06/03/3305904/0/en/cocrystal-pharma-appoints-james-sapirstein-biopharma-industry-leader-with-extensive-antiviral-development-experience-as-chief-executive-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T10:41:12", "published_display": "03 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP: Presentation Highlights CDI-988", "summary": "Cocrystal Pharma (NASDAQ: COCP) presented encouraging data for its antiviral drug CDI-988 for norovirus infection at the ICAR 2026 conference. The presentation highlighted CDI-988's novel mechanism of action, broad-spectrum coverage, promising pharmacokinetic/pharmacodynamic data", "url": "https://scr.zacks.com/news/news-details/2026/COCP-Presentation-Highlights-CDI-988-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-01T16:40:12", "published_display": "01 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Noble Financial Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Raises Target Price to $10", "summary": "Noble Financial has reiterated its Buy rating for Cocrystal Pharma (COCP.US) and increased the target price to $10. This signals a continued positive outlook from the firm regarding Cocrystal Pharma's stock performance and potential.", "url": "https://www.moomoo.com/news/post/70649605/noble-financial-maintains-cocrystal-pharma-cocpus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-05-28T00:39:39", "published_display": "28 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQUy1TOFZ0c0M1RE96aThuajRvZTRScmlSSE84clNpalo1bUZLcVpEcWszWW9pTUtYZUljX28xZ3d3Ym9JN1JWdGVzZnNyN0N3M0hpTS13a0dRYm92bXluZWtVV0VrSEpEcHJwZGFEXzZPaFJ5QWtid1lCbVBDSl9pMGFjOFd4VUdLRDJIUEJoelNPRGVCQlQyaElGeW9laTQ0TU1QODZnLW5EY0hpTXpzVVhXdWlxZWRCZlNMQ2pfN0JrTWlBdHlNMC0wYW9TOUJGMktJM2dfc0plLTBBaHdqY1VCWjlZdXJZRVlIWTB1LUZHaE5fRUtHdWNiRmotems5U1hvUEFWMGRIUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cocrystal-pharma-provides-business-reports-120000564.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:00:00+00:00", "published_display": "15 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cocrystal-pharma-presentation-icar-2026-200500988.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T20:05:00+00:00", "published_display": "30 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPSHI3Q1VQT2Q1aGRWclI0bHljRTdndGFkNEFoSTNFV0tPY29lWUhPU3M5R1J2UjVLdGJvdEpfYk12M241MUlPTnlEbjAxVkgzeFoxLVY2Q0d4SkVFOHZNVzBZT1dSOU1IYTRVQjkzYWZtelJ2M1FFaDhWbkw1X3NoTGdCSDdoUGZaMk80c2dzS2hWUnVwRC05MGZCMm5FMXljQXViYlZ0dXc2a014YXF6dzhUYUp2bHJyUW5Xd2ZOT20?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxOSkMtS0ktSzhYS1czRUJOTFpRM1JFSVduYmx5U3NtR3BmMDE3TzF5aUVVTURxZnFxelhnVnhjYlM0Rkh2Z2NGTU94NDNTTXBSRmR3eWpXWE1ZRnFWNkROUVB4R01IQW5sV1F3NmFTY0hqcUh1dElhbzgzS1BUUXVpRXNoUWRwMjF2aEt4ckJ0b3pORE41a01Tdk5HdHBRMFZzbjBpaE15V0daazZfMGxpNDF3d0E4RjNXT2FRdngxQS1wSXVId1pZcUp0MmJlSl9qZkhPVEFHSVg5N01MeWl5eWtkSG5HaHFldE1jX1Fua3JLbDRuLTBpbGNCWnZLUzFhTG5SaDRSd2pxSllEcU52dEVFOA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP Stock Soars 75% \u2014 What Is The Link To Cocrystal\u2019s Norovirus Treatment?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNb2h6OGJndjFid3dfVk53R3pIdVNrWWltaGU3RDk4ZHduVzh1dWh0eEdXSllnemVXTmM3dFJVcnRIN1BMR2tCelJxVGJlSWVGUzBnWlJJWldDYVdLYUR6bHNpWm9Ockk1YV9XZjd5eFZJeFNlUjhjVmdmVGpvZHdGX3JrYUMzWnd4dG1CMlgzZjhvdEU2NUFDMndDWQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9PYlhhZ0Myd3NDU3gzUDFtaWo3OFh5NXVDZk9FUTR1SEdoazROYS1TOV9qNnUtUmxsdHNlRDNjQVlhZVluUHpNeTFVaWl3cDNiZ3Q0ZnAwOWw0SnV6M2ZidjFNTFlBZld2b0N3bUhGbzV1U1I3V2xHX2pPYzNHZw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNbXRBUGxpZWFEa2xMMDBaRG1xMWphTUR4Yi1ENmR4RWlqcVJFeG8wS01zR3ZjUkJFRlpUQTNOU0RGdnVMcTc0X2gzdU9Jdi1hUUJWQ0RTV2loTDhhNnAzWXMzMGl3ZWx6TGtSX2h4SFJYLXlWdm51QXBjMVpHRTNicVh3?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cocrystal Pharma files to sell 5.74M shares of common stock for holders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNemFMNlZzYTI2TS0yZmJRX2hmWDhsQk8zY2cxV3pISWVIcjFnc3B6b1pHOTlrM1NLR0FkU2VBNmw3Mi15ck5OQjU2Vnp6ZmZXMVpvaUxmY2tFVS02M1k1enRmeFFnWEFjdVpucmRVcnVFN05KbjBpWFNJYTFwOE5iSzJXZ0VYTXVOa3VKNjN4SFo2Yjl6RHlaTkFKR2g2UXlKaGlVdkhGLVRFaEszRVZoazBveS1mVERNZWE0LUY5S3d0RV9HTHBkQ1kxejMzWDF6RHR3ZE05UF9qUFFPTHQ1U05zR3dtUQ?oc=5", "source_name": "MSN", "published_at": "2025-09-19T20:59:31+00:00", "published_display": "19 Sep 2025 20:59", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE05TTRyZjdUdWs2QUVON0dScFhaQktrNHVpV0pPTW96NU1QU0tuUkdlZzB0NHJaTlJudEVmalItb2VuTzhmTjhwbGE4RnpmZ1c1U1Fz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:20:57+00:00", "published_display": "25 Apr 2025 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1SM0I1NzlQNHpNbkdfVGZwX0xXcHhPWHdnYUxobzZRbVdSY3l6MDk2aDFyek1vem03VXpBQ2U0bWxJbV9NbHJfVy1DYlVRUQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-08-23T01:57:30+00:00", "published_display": "23 Aug 2020 01:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "What's Driving the Micro-Cap Mania in SKYQ and COCP", "summary": "This article examines the explosive premarket surges in micro-cap stocks Sky Quarry (SKYQ) and Cocrystal Pharma (COCP), driven by significant catalysts. SKYQ's rally is attributed to strategic Nevada refinery talks and rising Brent crude prices, despite its concerning financial h", "url": "https://www.kavout.com/market-lens/what-s-driving-the-micro-cap-mania-in-skyq-and-cocp", "source_name": "Kavout | AI", "published_at": "2026-07-11T14:11:13", "published_display": "11 Jul 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cocrystal Pharma Inc \u2013 FWB:8CC", "summary": "This article provides financial information for Cocrystal Pharma Inc (FWB:8CC) on the Frankfurt Stock Exchange, specifically focusing on its \"Price to book forward\" metric. The content indicates that the market is closed with no trades and gives a general overview of the company'", "url": "https://www.tradingview.com/symbols/FWB-8CC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-11T01:08:58", "published_display": "11 Jul 2026 01:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Holds Near Key Support After Slight Decline - PCR Extreme", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQcGk2N2FvS1NPOEpNNU95TE9HVUtJRVB0ZExabnE2Y1dKdXU1cHJEdVdaZFlVSlF1WFpfcldLcG1IblY2NkJod0FTOUg3Y053SjZwZ210TVR2d2ttY05US1otWVFHd1Yxa3Y0Z2JqeWNzM2V6OV9LZVA2N084WWZxNng2RFJFbHQ2MUI0N3JibUJlTEpnYkg4ZGZuNnYxR05vbUlQbGR4Y2hJV0lHb0E?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-08T16:34:26+00:00", "published_display": "08 Jul 2026 16:34", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP - Cocrystal Pharma Inc Dividends", "summary": "This page provides a detailed financial overview of Cocrystal Pharma Inc (COCP), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists dividend information (all showing as unavailable), performance metrics over different", "url": "https://finviz.com/stock?t=COCP&p=w&ty=dv&b=2", "source_name": "Finviz", "published_at": "2026-07-06T00:40:47", "published_display": "06 Jul 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Inches Up as Stock Tests Key Resistance Levels - Diamond Pattern", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNbHNSOHRSbkVIcnVkT0x3VDc3YVZubjVBQVhadjluSDZFdllYem9Zcl9zd0RXZGVLcFpvd0VCcUg5ZU1XTUpUM25RLWxRVGpKNzluZjVkWlJXWFFXWHhWNEx3MVU1cG10VUFMWmhhQlc5eEtVWXNObHZMZjBCLUtQS19JcXMya3BkUXA0R2RXSkNwN01tb3JacUpid1N3TVNucEJDWnNxcEhqaFlUS1I5WVJaUEZuaUZt?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cocrystal Pharma, Inc. \u2013 NASDAQ:COCP", "summary": "This page provides financial information for Cocrystal Pharma, Inc. (NASDAQ: COCP), specifically focusing on its forward price-to-sales ratio. It indicates that the company's market is currently closed with no trades. The content highlights the availability of financial data, new", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:10:43", "published_display": "27 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cocrystal Pharma, Inc. \u2013 NASDAQ:COCP", "summary": "The article focuses on the enterprise value to revenue forward metric for Cocrystal Pharma, Inc. (NASDAQ:COCP). It appears to be a financial data point or analysis, although no specific numerical data is provided in the content. The layout suggests it's a page from a financial tr", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:39:14", "published_display": "26 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "8CC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Cocrystal Pharma Inc (8CC) stock, including analyst price targets, historical performance data, and financial metrics. It highlights that analysts have a max estimated price of 8.61 EUR and a min of 6.89 EUR for 8CC. The piece also covers curr", "url": "https://www.tradingview.com/symbols/GETTEX-8CC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:59", "published_display": "26 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cocrystal Pharma Inc \u2013 LS:A3DWYX", "summary": "The article provides information regarding the \"Price to book forward\" for Cocrystal Pharma Inc (LS:A3DWYX) on TradingView. It appears to be a financial data point for the company, accessible through the platform's financials section. The content primarily lists navigation and fo", "url": "https://www.tradingview.com/symbols/LS-A3DWYX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T12:10:41", "published_display": "26 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc Actuals & Estimates (NASDAQ:COCP)", "summary": "The article provides actuals and estimates for Cocrystal Pharma, Inc. (COCP) stock, including historical price data, analyst forecasts, financial metrics, and company information. It details COCP's current price, market capitalization, earnings, revenue, and upcoming earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:14", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma(COCP) Stock Options Chain | Quotes & News", "summary": "This article provides access to the stock options chain, quotes, and news for Cocrystal Pharma (COCP). It serves as a resource for investors and analysts interested in detailed financial information and market performance related to the company.", "url": "https://www.moomoo.com/stock/COCP-US/options-chain?chain_id=Name1K9-3FXPhg.1ksbi40&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A39,%22f%22%3A%22www.moomoo.com%2Fus%2Fhant%2Flearn%2Fdetail-what-is-a-roth-ira-71734-220827203%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T09:10:43", "published_display": "26 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Cocrystal Pharma, Inc. (COCP) stock, including current price, historical performance, and analyst forecasts for 2027. It details analyst price targets, past earnings, revenue, and market capitalization, along with key financial dates like the ", "url": "https://www.tradingview.com/symbols/NASDAQ-COCP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T07:10:41", "published_display": "26 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cocrystal Pharma Inc (COCP), featuring its current price momentum score, support and resistance levels, and a detailed breakdown of various technical indicators and moving averages. The analysis suggests the stock is suitable for rang", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/technical", "source_name": "TradingKey", "published_at": "2026-06-22T19:09:28", "published_display": "22 Jun 2026 19:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article analyzes the financial health of Cocrystal Pharma Inc (COCP), noting its current financial score of 6.43, which ranks it 252 out of 389 in the Biotechnology & Medical Research industry. While its financial status is robust, its operating efficiency is low. The report", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/financial-health", "source_name": "TradingKey", "published_at": "2026-06-19T07:10:33", "published_display": "19 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Cocrystal Pharma Inc (COCP), listing major individual and institutional holders and their respective proportions. It includes information on shareholder types, institutional shareholding trends over several quarters, and recent sh", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T09:40:56", "published_display": "18 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on Cocrystal Pharma Inc (COCP) regarding its dividends and stock splits. It notes that the company has distributed no dividends over the past five years and details a series of 12-to-1 reverse merger stock splits that occurred on October 10, ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T00:40:14", "published_display": "18 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey attempts to provide a revenue breakdown for Cocrystal Pharma Inc (COCP) by business segments and regional contributions. However, it explicitly states that relevant data for these breakdowns have not been disclosed by the company. The page displays cu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T19:40:14", "published_display": "17 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc (COCP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cocrystal Pharma Inc (COCP), highlighting its current earnings forecast score of 8.00 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $8.00 with a \"Buy\" rating. The report also includes ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-cocp/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T05:09:46", "published_display": "17 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein as New CEO \u2013 Leadership Transition and Company Details", "summary": "Cocrystal Pharma, Inc. has announced the appointment of James Sapirstein as its new Chief Executive Officer, detailed in a recent 8-K filing. The appointment emphasizes a transparent transition with no related party transactions and includes stock-based incentives for Sapirstein,", "url": "https://www.minichart.com.sg/2026/06/09/cocrystal-pharma-appoints-james-sapirstein-as-new-ceo-leadership-transition-and-company-details/", "source_name": "Minichart", "published_at": "2026-06-09T15:10:19", "published_display": "09 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "James Sapirstein becomes CEO of Cocrystal Pharma (NASDAQ: COCP)", "summary": "Cocrystal Pharma, Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. He will receive an annual salary of $265,000, a target bonus of 50% of his base salary, and stock options for 235,000 shares, with a potential for an additional 235,00", "url": "https://www.stocktitan.net/sec-filings/COCP/8-k-cocrystal-pharma-inc-reports-material-event-ff2bd36f5245.html", "source_name": "Stock Titan", "published_at": "2026-06-09T11:10:19", "published_display": "09 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer", "summary": "Cocrystal Pharma Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Sapirstein brings extensive biopharma leadership and antiviral development experience, having led 23 product launches in his career. He replaces former Co-CEOs Sam Lee ", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cocrystal-pharma-appoints-james-sapirstein-110000949.html", "source_name": "Market source", "published_at": "2026-06-05T02:09:32", "published_display": "05 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer", "summary": "Cocrystal Pharma has appointed James Sapirstein as its new Chief Executive Officer. Sapirstein brings extensive experience in the pharmaceutical industry, and his leadership is expected to guide the company's strategic initiatives and growth. This appointment marks a significant ", "url": "https://www.moomoo.com/news/post/71000136/cocrystal-pharma-appoints-james-sapirstein-as-chief-executive-officer?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-04T23:40:01", "published_display": "04 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Inc. Plans to Appoint James Sapirstein as A Member of the Board of Directors", "summary": "Cocrystal Pharma Inc. announced its plan to appoint James Sapirstein to its Board of Directors. Sapirstein brings extensive pharmaceutical industry leadership, development, and business development experience, having led 23 product launches and held executive roles at Contravir P", "url": "https://www.marketscreener.com/news/cocrystal-pharma-inc-plans-to-appoint-james-sapirstein-as-a-member-of-the-board-of-directors-ce7f5ddcd18af220", "source_name": "www.marketscreener.com", "published_at": "2026-06-03T23:10:24", "published_display": "03 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) CEO awarded 235,000 stock options under 2025 plan", "summary": "Cocrystal Pharma Inc.'s CEO, James Sapirstein, has been granted 235,000 stock options under the company's 2025 Equity Incentive Plan. These options have an exercise price of $1.12 per share and will vest in four equal annual installments starting June 3, 2027, with an expiration ", "url": "https://www.stocktitan.net/sec-filings/COCP/form-4-cocrystal-pharma-inc-insider-trading-activity-c19e0de1498c.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:41:12", "published_display": "03 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) CEO James Sapirstein files initial Form 3", "summary": "Cocrystal Pharma's CEO, James Sapirstein, has filed an initial Form 3 with the SEC, establishing his status as an insider of the company. This filing is required for officers, directors, and large shareholders when they assume such roles, but it does not indicate any current stoc", "url": "https://www.stocktitan.net/sec-filings/COCP/form-3-cocrystal-pharma-inc-initial-statement-of-beneficial-ownership-daf6995ffce9.html", "source_name": "Stock Titan", "published_at": "2026-06-03T19:41:12", "published_display": "03 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP - Cocrystal Pharma Inc Stock Price and Quote", "summary": "This article provides a detailed stock quote and company overview for Cocrystal Pharma Inc (COCP), including financial data, performance metrics, and recent news releases. It also lists insider transactions by Director Phillip Frost. The company is a clinical-stage biotechnology ", "url": "https://finviz.com/stock?t=COCP", "source_name": "Finviz", "published_at": "2026-06-03T11:13:18", "published_display": "03 Jun 2026 11:13", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Antiviral executive James Sapirstein takes helm at Cocrystal Pharma", "summary": "Cocrystal Pharma (COCP) has appointed James Sapirstein as its new Chief Executive Officer, effective immediately, and plans to add him to the Board of Directors. Sapirstein brings extensive biopharma leadership and antiviral development experience, having participated in or led 2", "url": "https://www.stocktitan.net/news/COCP/cocrystal-pharma-appoints-james-sapirstein-biopharma-industry-leader-leavplspek84.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:41:12", "published_display": "03 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Veteran antiviral leader James Sapirstein to head Cocrystal Pharma (NASDAQ: COCP)", "summary": "Cocrystal Pharma (NASDAQ: COCP) has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Sapirstein, who brings extensive experience in the biopharma industry and antiviral development, will also join the Board of Directors. Former Co-CEOs Sam Lee", "url": "https://www.stocktitan.net/sec-filings/COCP/8-k-cocrystal-pharma-inc-reports-material-event-2e5a52653fc3.html", "source_name": "Stock Titan", "published_at": "2026-06-03T10:41:12", "published_display": "03 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Appoints James Sapirstein, Biopharma", "summary": "Cocrystal Pharma Inc. has appointed James Sapirstein as its new Chief Executive Officer, effective immediately. Mr. Sapirstein brings extensive biopharma industry leadership and antiviral development experience and will also join the company's Board of Directors. The previous Co-", "url": "https://www.globenewswire.com/news-release/2026/06/03/3305904/0/en/cocrystal-pharma-appoints-james-sapirstein-biopharma-industry-leader-with-extensive-antiviral-development-experience-as-chief-executive-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T10:41:12", "published_display": "03 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP: Presentation Highlights CDI-988", "summary": "Cocrystal Pharma (NASDAQ: COCP) presented encouraging data for its antiviral drug CDI-988 for norovirus infection at the ICAR 2026 conference. The presentation highlighted CDI-988's novel mechanism of action, broad-spectrum coverage, promising pharmacokinetic/pharmacodynamic data", "url": "https://scr.zacks.com/news/news-details/2026/COCP-Presentation-Highlights-CDI-988-article/default.aspx", "source_name": "Zacks Small Cap Research", "published_at": "2026-06-01T16:40:12", "published_display": "01 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Noble Financial Maintains Cocrystal Pharma(COCP.US) With Buy Rating, Raises Target Price to $10", "summary": "Noble Financial has reiterated its Buy rating for Cocrystal Pharma (COCP.US) and increased the target price to $10. This signals a continued positive outlook from the firm regarding Cocrystal Pharma's stock performance and potential.", "url": "https://www.moomoo.com/news/post/70649605/noble-financial-maintains-cocrystal-pharma-cocpus-with-buy-rating-raises", "source_name": "Moomoo", "published_at": "2026-05-28T00:39:39", "published_display": "28 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigJBVV95cUxQUy1TOFZ0c0M1RE96aThuajRvZTRScmlSSE84clNpalo1bUZLcVpEcWszWW9pTUtYZUljX28xZ3d3Ym9JN1JWdGVzZnNyN0N3M0hpTS13a0dRYm92bXluZWtVV0VrSEpEcHJwZGFEXzZPaFJ5QWtid1lCbVBDSl9pMGFjOFd4VUdLRDJIUEJoelNPRGVCQlQyaElGeW9laTQ0TU1QODZnLW5EY0hpTXpzVVhXdWlxZWRCZlNMQ2pfN0JrTWlBdHlNMC0wYW9TOUJGMktJM2dfc0plLTBBaHdqY1VCWjlZdXJZRVlIWTB1LUZHaE5fRUtHdWNiRmotems5U1hvUEFWMGRIUQ?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cocrystal-pharma-provides-business-reports-120000564.html", "source_name": "GlobeNewswire", "published_at": "2026-05-15T12:00:00+00:00", "published_display": "15 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cocrystal-pharma-presentation-icar-2026-200500988.html", "source_name": "GlobeNewswire", "published_at": "2026-04-30T20:05:00+00:00", "published_display": "30 Apr 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal's norovirus pill gets FDA fast track amid 685M yearly cases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPSHI3Q1VQT2Q1aGRWclI0bHljRTdndGFkNEFoSTNFV0tPY29lWUhPU3M5R1J2UjVLdGJvdEpfYk12M241MUlPTnlEbjAxVkgzeFoxLVY2Q0d4SkVFOHZNVzBZT1dSOU1IYTRVQjkzYWZtelJ2M1FFaDhWbkw1X3NoTGdCSDdoUGZaMk80c2dzS2hWUnVwRC05MGZCMm5FMXljQXViYlZ0dXc2a014YXF6dzhUYUp2bHJyUW5Xd2ZOT20?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxOSkMtS0ktSzhYS1czRUJOTFpRM1JFSVduYmx5U3NtR3BmMDE3TzF5aUVVTURxZnFxelhnVnhjYlM0Rkh2Z2NGTU94NDNTTXBSRmR3eWpXWE1ZRnFWNkROUVB4R01IQW5sV1F3NmFTY0hqcUh1dElhbzgzS1BUUXVpRXNoUWRwMjF2aEt4ckJ0b3pORE41a01Tdk5HdHBRMFZzbjBpaE15V0daazZfMGxpNDF3d0E4RjNXT2FRdngxQS1wSXVId1pZcUp0MmJlSl9qZkhPVEFHSVg5N01MeWl5eWtkSG5HaHFldE1jX1Fua3JLbDRuLTBpbGNCWnZLUzFhTG5SaDRSd2pxSllEcU52dEVFOA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "COCP Stock Soars 75% \u2014 What Is The Link To Cocrystal\u2019s Norovirus Treatment?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNb2h6OGJndjFid3dfVk53R3pIdVNrWWltaGU3RDk4ZHduVzh1dWh0eEdXSllnemVXTmM3dFJVcnRIN1BMR2tCelJxVGJlSWVGUzBnWlJJWldDYVdLYUR6bHNpWm9Ockk1YV9XZjd5eFZJeFNlUjhjVmdmVGpvZHdGX3JrYUMzWnd4dG1CMlgzZjhvdEU2NUFDMndDWQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Advances in Norovirus Study as Financial Challenges Loom", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE9PYlhhZ0Myd3NDU3gzUDFtaWo3OFh5NXVDZk9FUTR1SEdoazROYS1TOV9qNnUtUmxsdHNlRDNjQVlhZVluUHpNeTFVaWl3cDNiZ3Q0ZnAwOWw0SnV6M2ZidjFNTFlBZld2b0N3bUhGbzV1U1I3V2xHX2pPYzNHZw?oc=5", "source_name": "StocksToTrade", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma Advances Antiviral Trials Amid Financial Strategy Shift", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNbXRBUGxpZWFEa2xMMDBaRG1xMWphTUR4Yi1ENmR4RWlqcVJFeG8wS01zR3ZjUkJFRlpUQTNOU0RGdnVMcTc0X2gzdU9Jdi1hUUJWQ0RTV2loTDhhNnAzWXMzMGl3ZWx6TGtSX2h4SFJYLXlWdm51QXBjMVpHRTNicVh3?oc=5", "source_name": "timothysykes.com", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma files to sell 5.74M shares of common stock for holders", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNemFMNlZzYTI2TS0yZmJRX2hmWDhsQk8zY2cxV3pISWVIcjFnc3B6b1pHOTlrM1NLR0FkU2VBNmw3Mi15ck5OQjU2Vnp6ZmZXMVpvaUxmY2tFVS02M1k1enRmeFFnWEFjdVpucmRVcnVFN05KbjBpWFNJYTFwOE5iSzJXZ0VYTXVOa3VKNjN4SFo2Yjl6RHlaTkFKR2g2UXlKaGlVdkhGLVRFaEszRVZoazBveS1mVERNZWE0LUY5S3d0RV9HTHBkQ1kxejMzWDF6RHR3ZE05UF9qUFFPTHQ1U05zR3dtUQ?oc=5", "source_name": "MSN", "published_at": "2025-09-19T20:59:31+00:00", "published_display": "19 Sep 2025 20:59", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE05TTRyZjdUdWs2QUVON0dScFhaQktrNHVpV0pPTW96NU1QU0tuUkdlZzB0NHJaTlJudEVmalItb2VuTzhmTjhwbGE4RnpmZ1c1U1Fz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T01:20:57+00:00", "published_display": "25 Apr 2025 01:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cocrystal Pharma (COCP) Stock News & Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE1SM0I1NzlQNHpNbkdfVGZwX0xXcHhPWHdnYUxobzZRbVdSY3l6MDk2aDFyek1vem03VXpBQ2U0bWxJbV9NbHJfVy1DYlVRUQ?oc=5", "source_name": "Stock Titan", "published_at": "2020-08-23T01:57:30+00:00", "published_display": "23 Aug 2020 01:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 51, "sentiment_summary": {"positive": 12, "negative": 4, "neutral": 35, "score": 55, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 17.4, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 1.01, "latest_week": "2026-07-10", "one_week_move": -2.9, "four_week_move": 1.5, "twelve_week_move": -33.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.704609, "market_dynamics_buy_signal": false, "relative_strength": -28.359259, "fair_value_gap": -38.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.7038, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.9% over one week, +1.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 6}, {"label": "TradingKey", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "Moomoo", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-2.9% over one week, +1.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "What's Driving the Micro-Cap Mania in SKYQ and COCP"}], "updated_at": "2026-07-16T14:28:44.348398+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}